Savara Inc

Savara Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its sole program is MOLBREEVI (molgramostim inhalation solution), an inhaled biologic being developed for autoimmune pulmonary alveolar proteinosis (autoimmune PAP) and delivered through a proprietary eFlow Nebulizer System.

11.85

11.85

— Savara Inc
%
Lead product candidate100% MOLBREEVI is Savara's inhaled biologic candidate for autoimmune PAP.

Savara does not yet sell commercial products; its future customers would be patients with autoimmune PAP and the...

  • Autoimmune PAP patientsprimary

    Patients with autoimmune pulmonary alveolar proteinosis who would use MOLBREEVI if approved.

  • Specialist physicians and centersprimary

    Pulmonologists and specialty centers that diagnose, prescribe, and monitor treatment.

  • Payers and reimbursement authoritiessecondary

    Insurers and health systems that influence patient access and commercial uptake.

  • International partnerssecondary

    Potential collaborators for commercialization outside the U.S. and selected markets.

Savara is headquartered in the United States, with its principal office in Langhorne, Pennsylvania, and a majority of...

  • •Headquartered in Langhorne, Pennsylvania, United States
  • •Primary regulatory focus is the U.S. FDA for MOLBREEVI
  • •Also seeking approval in the EU and the UK
  • •May use collaboration arrangements outside the U.S.
  • •Remote workforce and European vendors add cross-border operating exposure

Savara's strategy is centered on advancing MOLBREEVI through regulatory approval and building a focused...

01
Regulatory approval for MOLBREEVIshort-term

Commercial value depends on obtaining approval for the sole product candidate.

02
Build commercialization capabilitiesmedium-term

A rare-disease launch requires specialized sales, access, and patient support infrastructure.

03
Pursue strategic partnerships outside the U.S.medium-term

International collaboration can extend reach while limiting direct operating complexity.

Savara is highly dependent on the clinical, regulatory, and eventual commercial success of a single product candidate,...

critical

Dependence on MOLBREEVI

The company has one product candidate, so failure in development or approval would leave no commercial portfolio.

Scope
Clinical, regulatory, and commercial execution
Materiality
high
high

Regulatory approval risk

FDA or other regulators may delay, request changes, or deny approval, pushing out commercialization.

Scope
United States, EU, UK
Materiality
high
high

Financing risk

The company has no product revenue and may need additional capital to fund development and launch.

Scope
Equity issuance, debt, grants, alliances
Materiality
high
medium

Commercial launch execution

Rare-disease commercialization requires specialized sales, access, and reimbursement capabilities.

Scope
U.S. specialty market
Materiality
medium
medium

Cybersecurity and remote-work risk

A distributed workforce and virtual operations increase exposure to phishing, malware, and data loss.

Scope
Remote employees and cloud/IT systems
Materiality
medium
medium

Debt covenant risk

Loan covenants could accelerate repayment or restrict operations if not met.

Scope
Hercules Loan Agreement
Materiality
medium
No product revenue
Revenue remains zero until commercialization begins
Debt accounting
Amortization and extinguishment gains/losses can affect net loss
Foreign currency transactions
FX gains/losses flow through other income (expense), net
Short-term investments
Can influence non-operating income and cash flow classification

PALVELLA THERAPEUTICS, INC.

PVLA · Pharmaceutical Preparations

Raphael Pharmaceutical Inc.

RAPH · Medicinal Chemicals & Botanical Products

Travere Therapeutics, Inc.

TVTX · Pharmaceutical Preparations

Spero Therapeutics, Inc.

SPRO · Pharmaceutical Preparations

Atara Biotherapeutics, Inc.

ATRA · Biological Products, (No Diagnostic Substances)

ZEVRA THERAPEUTICS, INC.

ZVRA · Pharmaceutical Preparations

: 29/04/2026